Trillium Therapeutics Joins Russell 2000® and 3000® Indices
CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market Russell…
